A pharmacokinetic (PK) pharmacodynamic (PD) driven first-in-human study of the oral class I PI3K inhibitor CH5132799, in patients with advanced solid tumors.
Aurelius Omlin(University of Zurich), Sarah P. Blagden(Churchill Hospital), Monsterrat Blanco(Royal Marsden NHS Foundation Trust), Chara Stavraka(King's College London), Keith Jones(Chugai Pharma (United States)), Simon P. Heaton(Institute of Cancer Research), Philippe A. Cassier(Centre Léon Bérard), Aneta Suder(Guy's Hospital), Udai Banerji(Institute of Cancer Research), James Spicer(King's College London), Shaun Decordova(Institute of Cancer Research), Rie Shiokawa(Chugai Pharma (United States)), Roshan Agarwal(Imperial College Healthcare NHS Trust), Michiyasu Inatani(Chugai Pharma (United States)), Lorna Pope(Institute of Cancer Research), Debashis Sarker(King's College - North Carolina), Kohei Noguchi(Chugai Pharma (United States)), David J. Pinato(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Suzanne Allan(Guy's Hospital), Jenny Prince(Chugai Pharma (United States))
Cited by 5
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer
|Nature reviews. Cancer|2015|1.4k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835
Multiple primary tumours: challenges and approaches, a review
|ESMO Open|2017|616